AnaptysBio (NASDAQ:ANAB) Shares Up 6.9% – Should You Buy?

AnaptysBio, Inc. (NASDAQ:ANAB)’s stock price rose 6.9% during mid-day trading on Tuesday . The stock traded as high as $36.54 and last traded at $37.1740. Approximately 102,333 shares were traded during trading, a decline of 86% from the average daily volume of 710,718 shares. The stock had previously closed at $34.77.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on ANAB. Stifel Nicolaus upped their price target on AnaptysBio from $55.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Guggenheim lifted their price objective on shares of AnaptysBio from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Wedbush reiterated an “outperform” rating and issued a $50.00 target price on shares of AnaptysBio in a research note on Monday, November 10th. Wall Street Zen raised shares of AnaptysBio from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $59.40.

AnaptysBio Stock Performance

The stock has a 50 day moving average price of $31.16 and a 200 day moving average price of $25.54. The company has a market capitalization of $1.04 billion, a P/E ratio of -13.35 and a beta of 0.16.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $1.58. The business had revenue of $76.32 million during the quarter, compared to the consensus estimate of $15.83 million. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. As a group, sell-side analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

Hedge Funds Weigh In On AnaptysBio

Institutional investors have recently bought and sold shares of the company. First Light Asset Management LLC raised its stake in shares of AnaptysBio by 433.3% in the first quarter. First Light Asset Management LLC now owns 4,633,602 shares of the biotechnology company’s stock valued at $86,139,000 after buying an additional 3,764,720 shares during the period. Assenagon Asset Management S.A. raised its stake in AnaptysBio by 4,852.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock valued at $25,719,000 after acquiring an additional 822,975 shares during the period. Caption Management LLC raised its stake in AnaptysBio by 106.3% in the 1st quarter. Caption Management LLC now owns 23,376 shares of the biotechnology company’s stock valued at $435,000 after acquiring an additional 394,634 shares during the period. Woodline Partners LP lifted its holdings in AnaptysBio by 63.1% during the first quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock valued at $14,705,000 after purchasing an additional 305,950 shares during the last quarter. Finally, 683 Capital Management LLC boosted its position in AnaptysBio by 155.6% during the second quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock worth $11,100,000 after purchasing an additional 304,373 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.